Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

In a clinical trial conducted by experts in the metastatic clear cell renal cell carcinoma (ccRCC) — a type of kidney cancer — treatment space, investigators highlighted the importance of tailoring ...

Suzanne Merrill discussed stratified surveillance algorithms after the treatment of localized renal cell carcinoma (RCC). Dr. Merrill poses the question ‘why should we care about surveillance ...

This source code is distributed as accompanying codes for the article “ Localization events-based sample drift correction for localization microscopy with redundant cross-correlation algorithm” in ...

The study emphasizes the need for further research to make exceptional responses more common in RCC treatment. In patients with RCC, exceptional response to immunotherapy may be related to clonal ...

The median progression-free survival was 30.3 months, and the median overall survival was not reached. The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor ...

Pedro Barata discussing strategies on how to optimize patient selection for the new standard of care in the adjuvant treatment of RCC. This discussion is from the previously presented abstracts ...